IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP - News), a market leader in laser transmyocardial revascularization (TMR), today announced that it has submitted a pre-IDE (Investigational Device Exemption) to the Food and Drug Administration to initiate a feasibility trial for its PHOENIX System in patients with refractory angina. The PHOENIX Combination Delivery System combines intramyocardial laser channeling with the delivery of a biologic substance. The PHOENIX received a CE MARK in 2006 and there have been over 50 clinical cases completed to date outside of the U.S.
